Arkolith/Insider Trading/NAMS/Form 4

Kooij Louise Frederika

Chief Accounting OfficerNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Dec 29, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$5.2M
Net Open-Market Flow
-$5.2M
Transactions
11
7 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 26, 2025Option exercise(M)39K$10.00$389K54K
Dec 26, 2025Sell(S)44K$35.30$1.5M15K
Dec 26, 2025Option exercise(M)5K$10.90$55K59K
Dec 24, 2025Option exercise(M)26K$10.00$260K41K
Dec 24, 2025Sell(S)26K$35.68$928K15K
Dec 23, 2025Option exercise(M)75K$10.00$751K90K
Dec 23, 2025Sell(S)75K$36.21$2.7M15K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 26, 2025Option exercise(M)5K—$0218K
Dec 26, 2025Option exercise(M)39K—$0140K
Dec 24, 2025Option exercise(M)26K—$0179K
Dec 23, 2025Option exercise(M)75K—$0205K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-335513) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML